 Zynerba Pharmaceuticals Inc. has presented data from the Phase 2 BRIGHT trial describing the tolerability and efficacy of its Zygel transdermal cannabinoid therapy in children and adolescents with autism spectrum disorder ASD over a longer-term, 38-week treatment period. 